SCHEMBL4174609

SCHEMBL4174609

COC(=O)C1(Cl)OC12CCC(C#N)(c1ccc(OC)c3oc4ccccc4c13)CC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 6/20 0.36
MAOA P21397 3/20 0.34
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
RAB9A P51151 1/20 0.34
PDE10A Q9Y233 1/20 0.33
PDE4A P27815 3/20 0.33
PDE4C Q08493 3/20 0.33
PDE4D Q08499 3/20 0.33
HDAC8 Q9BY41 2/20 0.32
CYP17A1 P05093 1/20 0.32
CYP19A1 P11511 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
KMT2A Q03164 2/20 0.31
DUSP3 P51452 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4520437 0.92 PDE4B (0.35) PDE4BMAOAKDM4ENPC1ALDH1A1
Bicarbonate SCHEMBL14856672 0.81 MAOA (0.39) PDE4BMAOAKDM4ENPC1ALDH1A1
SCHEMBL4012783 0.79 MAOA (0.43) PDE4BMAOAKDM4ENPC1ALDH1A1
SCHEMBL4008944 0.79 PDE4B (0.48) PDE4BMAOAKDM4ENPC1ALDH1A1
SCHEMBL6089966 0.76 PDE4A (0.57) PDE4BALDH1A1LMNAPDE4APDE4C
SCHEMBL4164099 0.75 PDE4B (0.38) PDE4BMAOAKDM4ENPC1ALDH1A1
SCHEMBL4013462 0.74 MAOA (0.36) PDE4BMAOAKDM4ENPC1ALDH1A1
SCHEMBL4012666 0.74 PDE4B (0.37) PDE4BMAOAKDM4ENPC1ALDH1A1
SCHEMBL4532164 0.74 MAOA (0.37) PDE4BMAOAKDM4ENPC1ALDH1A1
SCHEMBL4515229 0.74 MAOA (0.37) PDE4BMAOAKDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074106-B1 DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 MYLAN LAB LTD (IN) 2013-04-17 EP disclosed
US-8263648-B2 Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 Mylan Laboratories Ltd. (IN) 2012-09-11 US disclosed
US-20090281131-A1 DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 MYLAN LABORATORIES LIMITED (IN) 2009-11-12 US disclosed
EP-2074106-A1 DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 Matrix Laboratories Limited (IN) 2009-07-01 EP disclosed
WO-2008032171-A1 DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 MATRIX LABORATORIES LTD. (DE) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281131-A1 DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 PDE4A, PDE4B, PDE12 PDE4B 2/4885MAOA 148/4885KDM4E 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.